We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENGS:NASDAQEnergys Group Limited Analysis

Data as of 2026-03-31 - not real-time

$1.16

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Energys Group Limited trades at $1.16, well above its DCF‑derived fair value of $0.40, indicating a significant overvaluation despite a bullish MACD and an RSI of 64.6 that suggests momentum is still intact. The stock sits near the midpoint of its technical range, with a support level at $0.78 and resistance at $1.30, while the 20‑day SMA (0.97) and 50‑day SMA (0.95) sit below the current price, reinforcing a short‑term price cushion. However, volatility is extreme at 81% over 30 days and the historic max drawdown exceeds 94%, highlighting a highly unstable price environment.
Fundamentally, the company is in distress: revenue has fallen 43%, margins are deeply negative, and the balance sheet is strained with a debt‑to‑equity ratio above 400. The recent Nasdaq Determination Letter confirming a bid price below $1 for 30 consecutive days adds regulatory and listing risk, while the lack of dividend and zero earnings further erode investor confidence. Combined with a high PB ratio of 8.3 and modest market cap of $36 M, the outlook is fraught with liquidity and solvency concerns.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Nasdaq listing non‑compliance and potential delisting
  • Current price far exceeds DCF fair value
  • Extreme short‑term volatility and thin trading volume

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Persistently negative earnings and margins
  • High debt‑to‑equity ratio limiting financial flexibility
  • Unclear path to revenue recovery

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Fundamental structural weaknesses in profitability
  • Elevated regulatory and listing risk
  • Lack of dividend and cash flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth-43.20%
Profit Margin-30.11%
ROA-11.34%
Debt/Equity428.77
P/B Ratio8.3
Op. Cash Flow$-499782
Free Cash Flow$1.1M
Industry P/E28.4

Technical Analysis

TrendNeutral
RSI64.6
Support$0.78
Resistance$1.30
MA 20$0.97
MA 50$0.95
MA 200$2.96
MACDBullish
VolumeIncreasing
Fear & Greed Index74.61

Valuation

Fair Value$0.40
GradeOvervalued
TypeValue

Risk Assessment

Beta0.76
Volatility81.08%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.